Keros Therapeutics

Historical price data

Keros Therapeutics is a clinical-stage biotech focused on developing engineered ligand traps to modulate the TGF-β signaling pathway for serious disorders in hematology, pulmonary, and cardiovascular diseases. The company has advanced its lead asset, KER-050, into Phase 2 trials for myelodysplastic syndromes and myelofibrosis, and its second candidate, KER-012, into Phase 2 for pulmonary arterial hypertension and cardiovascular disorders. Its strategy leverages a selective, platform-based approach to target specific ligands within the TGF-β superfamily, aiming to improve therapeutic outcomes with potentially better safety profiles. Keros went public in 2020 and is building a compelling clinical data package to validate its technology.

Proprietary platform for engineering ligand traps—fusion proteins that act as decoy receptors to selectively sequester specific TGF-β superfamily ligands, modulating pathway signaling with high precision.